SGX Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- SGX Pharmaceuticals's estimated annual revenue is currently $7.6M per year.
- SGX Pharmaceuticals's estimated revenue per employee is $155,000
Employee Data
- SGX Pharmaceuticals has 49 Employees.
- SGX Pharmaceuticals grew their employee count by 0% last year.
SGX Pharmaceuticals's People
Name | Title | Email/Phone |
---|
SGX Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is SGX Pharmaceuticals?
N/A
Total Funding
49
Number of Employees
$7.6M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
SGX Pharmaceuticals News
2022-04-19 - Sensex drops 715 pts, Nifty holds 17150 in broad-based sell-off; banks sink
While Bank, Financial Services, Pharma, and Metal indices were the worst hit (down around 2 per cent each), Auto, FMCG, and IT indices were...
2022-04-17 - Sensex Adds Over 850 Points; Nifty Settles Below 17,400
Gland Pharmaceuticals: Nicomac Machinery is selling 20.45 lakh shares representing 1.5% stake in the company. Floor price has been set at Rs 3,118 per share...
2022-04-17 - SGX Nifty down 45 points; here's what changed for market while you were
sleeping
... Systems India, SM Gold and SE Power and Earum Pharmaceuticals are the companies that will announce their March quarter results today.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $5.7M | 49 | -30% | N/A |
#2 | $12.9M | 49 | -6% | N/A |
#3 | $3.5M | 49 | -2% | N/A |
#4 | $6.4M | 49 | 0% | N/A |
#5 | $12.9M | 49 | 0% | N/A |